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ABSTRACT
Objectives: The risks of identifying prostate cancer (PCa) in patients with serum total PSA
(tPSA) between 4 and 10 ng/dl are between 25 and 35%. There are no data in Brazil showing the
incidence of disease when all variables for PSA assessment are considered altogether, specifically
tPSA, free fraction, PSA velocity and PSA stratified by age. The objective in this work was to define
the incidence of disease in a population of men with abnormal values of PSA variables and normal
digital rectal examination.
Materials and Methods: Between 1998 and 2003, 273 prostate biopsies were performed by
the same radiologist and analyzed by the same pathologist. All patients had a normal digital rectal
examination and biopsy had been indicated due to tPSA above 4 ng/dl or free-to-total PSA ratio (F/T
PSA) below 15% or PSA velocity higher than 25% per year or a PSA level regarded as high for the
age range. The relationship between these parameters and the positivity for prostate caner was deter-
mined.
Results: Patients’ mean age was 63.8 years, and PCa was identified in 135 cases (49.5%).
The incidence of PCa, related to unitary variations in tPSA, ranged from the limits of 33 to 80%,
respectively, in tPSA < 3 and PSA between 15.1 to 20. When the other PSA parameters were assessed
(free PSA, PSA according to age, rise velocity) PCa was detected in more than 25.3% of cases.
Conclusion: When patients with normal digital rectal examination are selected for prostate
biopsy due to tPSA levels above 4 or F/T PSA ratio lower than 15% or PSA velocity higher than 25%
per year or high PSA for the age range, the incidence of PCa is quite higher than that observed in a
population selected exclusively with basis on total PSA value.
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INTRODUCTION
Prostate cancer (PCa) is the fourth cause of
death in men worldwide (9.2%) being surpassed only
by lung (18%), stomach (11.9%) and colon/rectum
cancer (9.4%) (1). According to data from the Bra-
zilian National Cancer Institute (INCA) and the Health
Ministry, prostate cancer is the second cause of death
for men in Brazil, being surpassed only by lung can-
cer. For 2003, it is estimated the occurrence of 32,240
new cases and 8,230 deaths dues to this cancer.
Due to the magnitude of the impact over pub-
lic health, strong efforts have been made aiming the pre-
vention, early diagnosis and treatment of this disease.
Strategies for increasing the early detection are focused
on the determination of prostate specific antigen (PSA)
in serum, digital rectal examination and transrectal ul-
trasonography (TRUS) with prostate biopsy (2).
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PSA measurement, considered as an isolated
method for screening PCa, offers some advantages in
relation to digital rectal examination of prostate or
TRUS. Result is quantitative, does not depend on the
examiner and blood drawing is better accepted by
patients (3).
In patients with benign prostate hyperplasia
(BPH) its concentration rises in 30 to 50% of cases.
Such increase is more pronounced in prostate cancer,
occurring in 25 to 92%, and is dependant on tumor
volume (4). It must be stressed that PSA is not pros-
tate cancer-specific, but tissue-specific, and several
benign conditions can affect its serum concentration
(5). Moreover, a number of studies indicate that not
every case of PCa cause an increase in PSA (6,7).
Despite these inconveniences, the use of PSA
for detecting PCa is a worldwide practice. Recently,
epidemiological studies showed a decrease in mor-
tality resulting from this disease of up to 20% in some
series where PSA was routinely dosed for screening
this neoplasia (8,9).
Data are favorable, but unarguably there are
limitations in the use of serum PSA for assessing
potential PCa cases. For this reason, new measure-
ments have appeared concerning the measurement of
this marker, including PSA discrimination by age,
PSA L/T ratio and PSA velocity, all three promote a
higher detection of this neoplasia (10).
Aiming to study the significance of PSA se-
rum levels in a population of men with normal digital
rectal examination of the prostate, the PSA param-
eters were assessed in association with the positivity
for prostate cancer in TRUS-guided prostate biop-
sies.
MATERIALS AND METHODS
We conducted a retrospective study of 273
transrectal ultrasonography-guided prostate biopsies,
performed by a single radiologist and analyzed by
the same pathologist, in the period from January 1998
to January 2003, in a single hospital.
The ultrasonography-guided prostate biopsy
was indicated according to criteria previously estab-
lished: cases with tPSA above 4 ng/dl, free/total PSA
ratio (F/T PSA) below 15%, PSA velocity higher than
25% per year and high PSA value for age as described
by Oesterling et al. in 1993 (11). The serum tPSA con-
centration was measured by immunometric method
with results in ng/ml, using various kits, according to
the laboratory where the test was performed.
The digital rectal examination was consid-
ered normal when no alterations were identified or, if
present, they were characteristic of BPH (prostate with
increased volume with fibroelastic consistency,
smooth surface, without nodules or hardening areas).
Patients with tPSA above 20 ng/ml, altered
digital rectal examination, cases of repeated prostate
biopsy and those submitted to previous treatment (PCa
and BPH) were excluded from the analysis.
Dada obtained were tabulated, evaluating the
incidence of prostate cancer, in men with normal digi-
tal rectal examination, in the following unitary varia-
tions for tPSA: lower than 3.0; from 3.1 to 4.0; from
4.1 to 5.0; from 5.1 to 6.0; from 6.1 to 7.0; from 7.1
to 8.0; from 8.1 to 9.0; from 9.1 to 10.0; from 10.1 to
15.0 and from 15.1 to 20; and in other PSA param-
eters: tPSA > 4; tPSA / age; tPSA 4 -10 and F/T PSA
< 15%; tPSA > 4 and PSA velocity > 25%/year; tPSA
2.6 - 4 and F/T PSA < 15%; tPSA < 4 and PSA veloc-
ity > 25%/year.
RESULTS
In the group under analysis of 273 patients
the mean age was 63.8 years (42 to 82 years) and 135
(49.5%) presented prostate cancer.
tPSA values and the number of prostate frag-
ments removed in the biopsy are represented in
Table-1.
The prevalence of PCa in relation to tPSA
categories ranged between the extremes of 33 to
78.6%, respectively, in tPSA < 3 and PSA between
15.1 and 20 (Table-2).
The criteria for indication of biopsy assess-
ing the various PSA parameters in relation to the in-
cidence of PCa are showed in Table-3.
DISCUSSION
The present work retrospectively assessed
273 prostate biopsies in men without abnormalities
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Table 1 – Age, total PSA (tPSA) and number of fragments in biopsies from 273 patients.
PCa in Biopsy
Positive = 135 cases
Negatives = 138 cases
Total = 273 cases
  Mean Age (years)
           (mean)
       (min/max)
            65.3
          (46/82)
            62.4
          (42/81)
            63.8
Mean tPSA (ng/dl)
         (mean)
      (min/max)
            8.4
        (1.4/20)
            8.3
        (0.5/20)
            8.35
No. of  Fragments
         (mean)
       (min/max)
             9.9
           (5/25)
           12.7
          (5/32)
           11.3
PCa = prostate cancer
on the digital rectal examination of the prostate that
presented tPSA levels between 0.5 and 20 ng/dl. Bi-
opsy was indicated in cases of abnormal tPSA values
or F/T PSA ratio or PSA velocity/year or PSA for
age. The results obtained show that the incidence of
Table 2 – Prevalence of prostate cancer in patients with
normal digital rectal examination.
Total PSA (ng/dl)
< 3
3.1 a 4
4.1 a 5
5.1 a 6
6.1 a 7
7.1 a 8
8.1 a 9
9.1 a 10
10.1 a 15
15.1 a 20
No. of
 Cases
     9
 15
 27
 30
 40
 27
 31
 21
 59
 14
 Cancer
  No.       %
   3         33.3
 7         46.7
13        48.1
14        46.7
21        52.5
14        51.8
15        48.4
11        52.4
28        47.5
11        78.6
Table 3 – Incidence of prostate cancer in relation to various PSA parameters for indicating biopsy.
PSA Parameters (ng/ml)
tPSA > 4
tPSA 4 – 10 + F/T PSA < 15%
tPSA /Age
tPSA > 4 + PSA Velocity > 25%/year
tPSA < 4 + PSA Velocity > 25%/year
tPSA 2.6 - 4 + F/T PSA < 15%
Total
No. of Cases
      131
       71
       41
       12
       12
         6
     273
     Cancer
 No.         %
 66         24.2
 35         12.8
 20           7.3
   6           2.2
   5           1.9
   3           1.1
135        49.5
prostate cancer was superior to that observed when
campaigns for detecting the disease are performed
using tPSA levels only.
The present work the incidence of PCa was
49.5%, superior to that observed by Candas et al. (12),
who performed an investigational population study
without assessing PSA parameters. The results are
presented in Table-4. However, the values obtained
find a parallel in literature in large series where sev-
eral PSA measures were assessed, such as those by
Han et al. with 2404 patients, by Guillonneau et al.
with 1000 cases and by Catalona et al. with 1870 pa-
tients, where the frequency of cases with localized
prostate cancer and normal digital rectal examination
(stages T1a, T1b and T1c) was, respectively, 44%,
67% and 39% (13-15).
In another study, with 1280 prostate biopsies,
the authors reported 34% OF prostate neoplasia when
there was any alteration in PSA associated to normal
digital rectal examination (16). Cooner et al. (3) found
lower figures, ranging between 9% when tPSA was
lower than 4 ng/dl and 31% in patients with tPSA >10.
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The results presented surpass the values of
incidence of PCa found in investigational popula-
tion works for research on prostate neoplasia, which
often do not consider the various PSA parameters.
The present study shows that the prostate biopsy in
men with normal digital rectal examination, when
other PSA measurements are considered, promotes
an increase in the diagnosis of neoplasia as demon-
strated in Table-3, and that maybe theses cases would
be undiagnosed if we assessed only by isolated PSA
measurement. Gann et al. obtained a higher detec-
tion of PCa (15 to 25%), when they associated the
assessment of free PSA values (10). Another factor
that may be associated with these results is the higher
number of fragments obtained in the prostate biopsy
which showed an average above 11 in this work
(Table-1).
Ravery et al. (17) reported a series with 303
patients where the increase of fragments in prostate
biopsy (12 fragments) promoted the diagnosis in ad-
ditional 17% of cases. In a study with 2299 consecu-
tive biopsies, Presti et al. (18) demonstrated that a
higher number of fragments increases the detection
of this neoplasia, with such indication being more rel-
evant in men under 60 years-old or in those with tPSA
< 7 ng/ml.
The results demonstrate that PSA dosage has
certain limitations, however when all parameters of
PSA measurements are used, such as stratification by
age, fractioning or rise velocity, the disease can be
diagnosed in a higher number of patients.
Table 4 – Prevalence of prostate cancer according to strati-
fied values of total PSA (tPSA).
tPSA (ng/dl)
< 3
3.1 a 4
4.1 a 5
5.1 a 7
7.1 a 10
10.1 a 20
* Present Study
   No.            %
 3             33.3
 7             46.7
 13           48.1
 35           50.0
 40           50.6
 39           53.4
** Candas et al. (ref. 17)
           No.            %
         37             2.0
         41             6.0
         31             8.3
         56             13.9
         52             22.5
         59             31.4
* = Population whose biopsy was indicated by change in any
parameter for PSA assessment; ** = Screening work for detec-
tion of PCa without considering PSA levels.
CONCLUSION
When patients with normal digital rectal ex-
amination are selected for prostate biopsy due to tPSA
levels above 4 or F/T PSA ratio lower than 15% or
PSA velocity higher than 25%/year or high PSA value
for age, the incidence of PCa is largely superior to
that observed in a selected population assessed ex-
clusively through serum tPSA levels.
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